Previous 10 | Next 10 |
home / stock / awknf / awknf news
Licenses Awakn Kare and Certain Healthcare Intellectual Property Assets to New Owners Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics to t...
Toronto, Ontario--(Newsfile Corp. - June 27, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the " Company "), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce th...
Conference hosted by M-Vest, Awakn to present on Thursday, June 22nd at 9:00 A.M. ET Toronto, Ontario--(Newsfile Corp. - June 19, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the " Company "), a clinical-stage biotechnology company developing therapeutics to treat add...
Toronto, Ontario--(Newsfile Corp. - June 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the " Company "), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce th...
Term Sheet Signed to License Healthcare Intellectual Property to UK Healthcare Consortium Exclusively in the UK Market Strategic Review of Norwegian Healthcare Clinics Business Unit Initiated Toronto, Ontario--(Newsfile Corp. - June 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AW...
2023-04-28 09:04:54 ET Awakn Life Sciences press release ( OTCQB:AWKNF ): Q4 Revenue of $471.82M (+130.9% Y/Y). As of January 31, 2023, the Company had approximately $550,866 in cash. For further details see: Awakn Life Sciences reports Q4 results
Annual Revenue Increased by 534% Toronto, Ontario--(Newsfile Corp. - April 28, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), annou...
2023-04-26 09:09:07 ET Biotechnology company Awakn Life Sciences ( OTCQB:AWKNF ) said on Wednesday that it is launching an up to $3M units offering. The non-brokered private placement financing will see the issuance of up to 6.5M units at $0.46 per unit. The company has closed...
Toronto, Ontario--(Newsfile Corp. - April 26, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the " Company "), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce a non-brokered p...
Phase III Trial Will Assess Ketamine-Assisted Therapy for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addicti...
News, Short Squeeze, Breakout and More Instantly...
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Diso...
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), annou...
Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is ...